These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 11512521)
1. Does resistance to apoptosis affect clinical response to antitumor drugs? Borst P; Borst J; Smets LA Drug Resist Updat; 2001 Apr; 4(2):129-31. PubMed ID: 11512521 [No Abstract] [Full Text] [Related]
2. Apoptosis is critical for drug response in vivo. Schmitt CA; Lowe SW Drug Resist Updat; 2001 Apr; 4(2):132-4. PubMed ID: 11512522 [No Abstract] [Full Text] [Related]
3. The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis. Mace TA; Yamane N; Cheng J; Hylander BL; Repasky EA Immunol Invest; 2006; 35(3-4):279-96. PubMed ID: 16916755 [TBL] [Abstract][Full Text] [Related]
4. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
5. [The inhibition of apoptosis in cancer cells resistant to anticancer drugs]. Nowak R; Tarasiuk J Postepy Biochem; 2004; 50(4):330-43. PubMed ID: 15957528 [No Abstract] [Full Text] [Related]
6. Therapeutic potential of nitric oxide in cancer. Bonavida B; Khineche S; Huerta-Yepez S; Garbán H Drug Resist Updat; 2006 Jun; 9(3):157-73. PubMed ID: 16822706 [TBL] [Abstract][Full Text] [Related]
7. Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. Park H; Aiyar SE; Fan P; Wang J; Yue W; Okouneva T; Cox C; Jordan MA; Demers L; Cho H; Kim S; Song RX; Santen RJ Cancer Res; 2007 Jun; 67(12):5717-26. PubMed ID: 17575138 [TBL] [Abstract][Full Text] [Related]
8. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Nakshatri H; Rice SE; Bhat-Nakshatri P Oncogene; 2004 Sep; 23(44):7330-44. PubMed ID: 15286701 [TBL] [Abstract][Full Text] [Related]
9. The effect of intracellular ascorbate on the susceptibility of HL60 and Jurkat cells to chemotherapy agents. Gokhalé P; Patel T; Morrison MJ; Vissers MC Apoptosis; 2006 Oct; 11(10):1737-46. PubMed ID: 16951922 [TBL] [Abstract][Full Text] [Related]
10. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Hazlehurst LA; Landowski TH; Dalton WS Oncogene; 2003 Oct; 22(47):7396-402. PubMed ID: 14576847 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Uzzo RG; Haas NB; Crispen PL; Kolenko VM Cancer; 2008 Apr; 112(8):1660-71. PubMed ID: 18278811 [TBL] [Abstract][Full Text] [Related]
12. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line. Spierings DC; de Vries EG; Vellenga E; de Jong S Cell Death Differ; 2003 Jul; 10(7):808-22. PubMed ID: 12815464 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Fantin VR; Richon VM Clin Cancer Res; 2007 Dec; 13(24):7237-42. PubMed ID: 18094401 [TBL] [Abstract][Full Text] [Related]
14. Drug resistance mechanisms in cancer cells: a proteomics perspective. Verrills NM; Kavallaris M Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435 [TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells. Milner AE; Palmer DH; Hodgkin EA; Eliopoulos AG; Knox PG; Poole CJ; Kerr DJ; Young LS Cell Death Differ; 2002 Mar; 9(3):287-300. PubMed ID: 11859411 [TBL] [Abstract][Full Text] [Related]
16. The role of caspase-8 in resistance to cancer chemotherapy. Kim PK; Mahidhara R; Seol DW Drug Resist Updat; 2001 Oct; 4(5):293-6. PubMed ID: 11991682 [TBL] [Abstract][Full Text] [Related]
17. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapy resistance of glioblastoma stem cells. Eramo A; Ricci-Vitiani L; Zeuner A; Pallini R; Lotti F; Sette G; Pilozzi E; Larocca LM; Peschle C; De Maria R Cell Death Differ; 2006 Jul; 13(7):1238-41. PubMed ID: 16456578 [No Abstract] [Full Text] [Related]
19. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels. Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839 [TBL] [Abstract][Full Text] [Related]
20. Overcoming drug resistance in patients with metastatic breast cancer. Wong ST; Goodin S Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]